双倍剂量氯吡格雷治疗CYP2C19中间代谢型老年急性心肌梗死患者的效果
作者:
作者单位:

(首都医科大学附属北京世纪坛医院心血管内科,北京 100038)

作者简介:

通讯作者:

中图分类号:

R541.4;R592

基金项目:


Efficacy of double dose clopidogrel in treatment of acute myocardial infarction in elderly patients with intermediate metabolic CYP2C19 metabolism
Author:
Affiliation:

(Department of Cardiology, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China)

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的 探讨双倍剂量氯吡格雷治疗CYP2C19中间代谢型老年急性心肌梗死患者(AMI)的临床效果。方法 入选2016年8月至2018年8月北京世纪坛医院心血管内科收治的CYP2C19中间代谢型老年AMI患者196例,随机数表法分为研究组和对照组,每组98例。2组患者均行经皮冠状动脉介入(PCI)术,研究组患者术后首次口服氯吡格雷300mg后150mg/次,服用3个月后改为75mg/次。对照组患者首次口服氯吡格雷300mg后75mg/次。2组患者均服药1年,1次/d。比较2组患者治疗前后心功能相关指标和白细胞介素-8(IL-8)及C-反应蛋白(CRP)水平,以及临床疗效、不良反应发生率和复发率。应用SPSS 22.0统计软件对数据进行分析。依据数据类型采用t检验或χ2检验进行组间比较。结果 和对照组相比,研究组患者治疗后QRS[(4.74±0.81)和(5.68±0.63)分]、梗死面积[(13.86±2.47)%和(17.23±3.02)%]、肌钙蛋白[(1.08±0.25)和(3.12±0.77)μg/L]、肌酸激酶同工酶-MB[(45.82±8.45)和(55.83±10.26)U/L]、IL-8[(39.54±8.22)和(55.28±11.64)μg/L]和CRP[(5.22±0.86)和(7.13±0.92)mg/L]水平低,左心室射血分数[(52.90±5.83)%和(44.93±5.46)%]水平高,差异均具有统计学意义(P<0.05)。研究组相比对照组总有效率[89.80%(88/98)和78.57%(77/98)]高,不良反应发生率[4.08%(4/98)和11.22%(11/98)]和复发率[2.04%(2/98)8.16%和(8/98)]低,差异均具有统计学意义(P<0.05)。结论 双倍剂量氯吡格雷治疗不耐受替格瑞洛CYP2C19中间代谢型老年AMI患者具有较好的临床疗效,不良反应发生率和复发率低。

    Abstract:

    Objective To investigate the efficacy of double dose of clopidogrel in the treatment of acute myocardial infarction (AMI) in the elderly patients with ticagrelor CYP2C19 intermediate metabolism. Methods A total of 196 elderly patients with acute myocardial infarction were enrolled, who were admitted to the Cardiology Department in Beijing Shijitan Hospital from August 2016 to August 2018. All patients were found to be of CYP2C19 intermediate metabolism and randomized into the study group and control group (98 in each group). The two groups underwent percutaneous coronary intervention (PCI). The study group took oral clopidogrel at 300mg for the first time after surgery, then at 150mg once for three months before shifted to 75mg once. The control group took oral clopidogrel at 300mg for the first time after surgery and then at 75mg once. Both groups took medication once daily for 1 year. The two groups were compared in cardiac function related indicators and inflammatory factors interleukin-8 (IL-8) and C-reactive protein (CRP) levels before and after treatment as well as clinical efficacy, adverse reaction rate and recurrence rate. SPSS statistics 22.0 was used to analyze the data. Student′s t test or Chi-square test was employed for intergroup comparison. Results Compared with the control group after treatment, the study group had lower QRS [(4.74±0.81) vs (5.68±0.63) score], myocardial infarction [(13.86±2.47)% vs (17.23±3.02)%], cardiac troponin [(1.08±0.25) vs (3.12±0.77)μg/L], creatine kinase isoenzyme-MB[(45.82±8.45) vs (55.83±10.26)U/L], IL-8 [(39.54±8.22) vs (55.28±11.64)μg/L] and CRP[(5.22±0.86) vs(7.13±0.92) mg/L], but higher left ventricular ejection fraction [(52.90±5.83)% vs (44.93±5.46)%], the difference beingstatistically significant. The total effective rate was significantly higher in the study group than the control group [89.80%(88/98) vs78.57%(77/98)], but the incidence of adverse reactions [4.08%(4/98) vs 11.22%(11/98)] and recurrence rate [2.04%(2/98) vs 8.16%(8/98)] in the former was significantly lower than the latter, the differences being statistically significant. Conclusion Double dose of clopidogrel has a good clinical efficacy in the treatment of acute myocardial infarction in the elderly patients with ticagrelor CYP2C19 intermediate metabolism with low incidence of adverse reactions and recurrence rate.

    参考文献
    相似文献
    引证文献
引用本文

赵博,彭建军,任利辉.双倍剂量氯吡格雷治疗CYP2C19中间代谢型老年急性心肌梗死患者的效果[J].中华老年多器官疾病杂志,2020,19(5):355~359

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2019-08-17
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2020-06-02
  • 出版日期: